FDA Approves Expanded Indications for CF Drugs Alyftrek, Trikafta
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Tag: Trikafta
All
Latest
FDA Approves Expanded Indications for CF Drugs Alyftrek, Trikafta
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Read More
Most Children with CF Achieve Normal Lung Function with Triple Combination Therapy, Study Finds
An observational one-year study found the therapy significantly reduced lung disease severity and prevented disease progression in children aged 6 to 11 with cystic fibrosis.
Read MoreHealth Canada OKs Trikafta for Younger Children With Cystic Fibrosis
Health Canada granted market authorization for the expanded use of Trikafta to include children with cystic fibrosis ages 2-5 years who have at least one copy of the F508del mutation in the CFTR gene.
Read MoreFDA Approves Trikafta For Pediatric Cystic Fibrosis
The FDA has approved the use of the Trikafta therapy to treat cystic fibrosis (CF) in children aged 6 to 11, making the therapy the first approved treatment for CF in the age group.
Read More
Study Uses Smartphone to Track Cystic Fibrosis
An observational study supported by the CF Foundation will monitor real-world experience with Trikafta.
Read MoreTrikafta triple-combo Therapy Safe for Cystic Fibrosis Patients Ages 6-11
According to a study published in AJRCCM, Vertex Pharma’s Trikafta (elexacaftor/tezacaftor/ivacaftor) is safe and efficacious in children 6 through 11 years of age with at least one F508del-CFTR allele. The safety and...
Read More
Top 10 Medical Innovations for 2021 Include Trikafta, Bubble CPAP
Cleveland Clinic announced the Top 10 Medical Innovations for 2021., which include the cystic fibrosis therapeutic Trikafta (#4), and bubble CPAP technology for preemies (#6).
Read More
How Has COVID-19 Affected Therapy Adherence in Cystic Fibrosis Patients?
Clinicians say a combination of factors have led to improved therapy adherence and disease management in young cystic fibrosis patients since the outset of the novel coronavirus pandemic.
Read More
Survey: Cystic Fibrosis Patients Receiving CFTR Modulators Had More Positive Health Outlooks
Cystic fibrosis patients being treated with a CFTR modulator had more positive outlooks on their futures, treatment plans, and healthcare professionals.
Read More
Trikafta Approved by FDA for Cystic Fibrosis
Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene, which is estimated to represent 90% of the cystic fibrosis population.
Read More
Vertex Reports Very Positive Ph1/Ph2 Data on Triple Therapies for CF
Vertex Pharmaceuticals Inc has reported positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF).
Read More